Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a weekend steroid pill stop vitiligo spreading in kids?

NCT ID NCT07353801

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 4 times

Summary

This study tests whether taking dexamethasone pills twice a week for 3 months can stop active vitiligo from spreading in children aged 4 to 9. Researchers will also monitor side effects, especially on growth and bone health. The goal is to control the disease, not cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

22 people

The number who actually took part.

Started

Feb 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

4 to 9 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Active (VIDA +3 \& +4) non segmental vitiligo * Age between 4-9yrs * Males and Females * Children with height measurements within the percentile range 5-95% of normal values for their age. Exclusion Criteria: * Segmental vitiligo. * Stable vitiligo. * History of endocrine disorders (growth hormone deficiency, thyroid disorders) * Growth disorders (Turner's syndrome, Klinefelter's syndrome) * Systemic diseases likely to affect growth (IBD, chronic renal failure)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-segmental vitiligo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dermatology Outpatient Clinic, Kasr al Ainy Teaching Hospital, Cairo University

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.